Academic Journal
Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study
| العنوان: | Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study |
|---|---|
| المؤلفون: | Buysschaert, Martin, Baeck, Marie, Preumont, Vanessa, Marot, Liliane, Hendrickx, Emilie, Van Belle, Astrid, Dumoutier, Laure |
| المساهمون: | UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Service d'anatomie pathologique |
| المصدر: | British Journal of Dermatology, Vol. 171, no. 1, p. 155-161 (2014) |
| بيانات النشر: | Blackwell Scientific Publications |
| سنة النشر: | 2014 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| الوصف: | BACKGROUND: A few case reports suggest that incretin-based therapies could improve psoriasis in patients with type 2 diabetes, the mechanism(s) of which remain unclear. OBJECTIVES: To determine the effects after 16-20 weeks of treatment with a glucagon-like peptide (GLP)-1 analogue on clinical severity and histopathological aspects of psoriasis in patients with type 2 diabetes, and to examine the presence of γδ T cells and the expression of interleukin (IL)-17 in psoriasis before and after treatment. METHODS: Seven patients with type 2 diabetes and psoriasis were followed. Psoriasis Area and Severity Index (PASI) was measured at baseline (T0) and after 7 ± 1 (T1) and 18 ± 2 (T2) weeks' treatment with exenatide/liraglutide. The histopathological pattern of psoriasis, and flow cytometry and immunological data (γδ T-cell percentage and IL-17 expression) were obtained from psoriatic and control sites. RESULTS: The mean PASI decreased from 12·0 ± 5·9 to 9·2 ± 6·4 (P = 0·04). Histological analysis showed a reduction in epidermal thickness after treatment. The dermal γδ T-cell percentage was higher in psoriatic lesions than in control specimens (P = 0·03), as was IL-17 expression (P = 0·018). A reduction of γδ T cells from 6·7 ± 4·5% to 2·7 ± 3·8% (P = 0·05) was demonstrated in the six patients with improved/unchanged PASI. A correlation between PASI and γδ T-cell percentage evolution during therapy (T2-T0) was noted (r = 0·894, P = 0·007). IL-17 was reduced in the four patients with the highest PASI reductions. CONCLUSIONS: The administration of a GLP-1 analogue improved clinical psoriasis severity in patients with type 2 diabetes. This favourable outcome was associated with a decrease of dermal γδ T-cell number and IL-17 expression. Further studies are needed to establish long-term efficacy in (diabetic) patients with psoriasis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | Ndonga |
| تدمد: | 0007-0963 1365-2133 |
| Relation: | boreal:157540; http://hdl.handle.net/2078.1/157540; info:pmid/24506139; urn:ISSN:0007-0963; urn:EISSN:1365-2133 |
| DOI: | 10.1111/bjd.12886 |
| الاتاحة: | http://hdl.handle.net/2078.1/157540 https://doi.org/10.1111/bjd.12886 |
| Rights: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.7A74268B |
| قاعدة البيانات: | BASE |
| تدمد: | 00070963 13652133 |
|---|---|
| DOI: | 10.1111/bjd.12886 |